Skip to main content
Caplight Logo









Regenacy Pharmaceuticals

Regenacy Pharmaceuticals

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://regenacy.com/

Last Round

Series B

Aug 24, 2022

Total Funding Raised

$39.3M

Company Overview

Regenacy Pharmaceuticals is a biopharmaceutical company that develops innovative therapeutic drugs using a novel, disease-modifying approach to treat peripheral neuropathy and related conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

HDAC6 inhibitorperipheral neuropathyricolinostatbiotech startupnerve regenerationclinical-stage biotechdiabetic neuropathysmall-molecule therapydrug developmentCharcot-Marie-Tooth diseaseCMTorphan drugclinical trialneurodegenerative diseasebiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Regenacy Pharmaceuticals Comparables

Compare Regenacy Pharmaceuticals with similar companies based on industry and business-model similarity.

Regenacy Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Augustine Therapeutics
91%
Novaremed AG
83%
WinSanTor
81%

Regenacy Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 24, 2022
Series AMar 25, 2020

Regenacy Pharmaceuticals Investors

Notable investors and investment history

Regenacy Pharmaceuticals investors
InvestorRounds
Taiwania CapitalSeries B, Series A
Bencao CapitalSeries A, Series B
Yonjin CapitalSeries A
Viva BiotechSeries A
TA YA VENTURE HOLDINGS LIMITEDSeries A
Yonjin CapitalSeries A
Cobro VenturesSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 24, 2022

    $9.3M round led by Cobro Ventures.

Regenacy Pharmaceuticals Filings

Explore SEC and related filing metadata, where available.

Regenacy Pharmaceuticals filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Regenacy Pharmaceuticals's valuation, stock price, and market status.

Is Regenacy a public or private company?

Regenacy is a private company.

What is the current stock price of Regenacy?

Regenacy is a private company with no public stock price. No recent secondary market data is available.

How much is Regenacy worth (valuation)?

Valuation information for Regenacy is not publicly available.

Can I buy Regenacy stock?

Regenacy shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Regenacy's last funding round?

Regenacy's most recent funding round was Series B on August 24, 2022.

Who are the main investors in Regenacy?

Key investors in Regenacy include Cobro Ventures.

Will Regenacy IPO soon?

No public IPO plans have been announced for Regenacy.

How can I track Regenacy secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Regenacy's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range1
Year Founded2016
Last FundingAug 24, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?